Skip to content

Epicutaneous Testing of Cosmetics for Skin Compatibility

Epicutaneous Testing of Cosmetic Products to Determine Skin Compatibility

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03024671
Enrollment
180
Registered
2017-01-19
Start date
2017-02-10
Completion date
2025-12-31
Last updated
2024-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatitis

Brief summary

The dermatological testing of cosmetic products which are new on the market, or existing products with novel formulations is common and a useful procedure, yet necessary to alleviate common irritants and contact allergic reactions. Cosmetic products contain a range of substances that may be considered as potential irritants or contact allergens. In order to estimate that risk, cosmetics are tested by applying patch tests.

Detailed description

The dermatological testing of cosmetic products which are new on the market, or existing products with novel formulations is common and a useful procedure, yet necessary to alleviate common irritants and contact allergic reactions. Cosmetic products contain a range of substances that may be considered as potential irritants or contact allergens. In order to estimate that risk, cosmetics are tested by applying patch tests, as with allergic reactions.

Interventions

OTHERPatch test application

test patch with cosmetic product will be applied to the back

Sponsors

Mibelle AG
CollaboratorINDUSTRY
Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and women older than 18 years old * Persons undergoing a diagnostic patch test for reason of a skin disease * Signed written informed consent

Exclusion criteria

* Acute skin inflammation and eczema on the back * Systemic corticosteroid and immunosuppressive therapy as well as UV exposure of the back within the last 4 weeks * Topical corticosteroids used on the back within the last two weeks

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with positive patch test reactions to cosmetics4 weeksInflammation of Skin at test patch location

Countries

Switzerland

Contacts

Primary ContactDagmar Simon, MD
dagmar.simon@insel.ch+41 31 632 2278

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026